← back to search

Kelli Greene

National Institute of Allergy and Infectious Diseases · US
Area of research
Virology · Infectious Diseases
Research interest
Research interests include Virology, Antibody, Biology, Human immunodeficiency virus (HIV), Neutralization, and Immunology.
h-index
citations
2,113
works
13
NIH funding
primary concept
email

Recent publications

Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
Science 2025cited by 51position: middledoi
Precise targeting of HIV broadly neutralizing antibody precursors in humans
Science 2025cited by 35position: middledoi
Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site
Science Immunology 2024cited by 36position: middledoi
Vaccination induces HIV broadly neutralizing antibody precursors in humans
Science 2022cited by 265position: middledoi
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
Journal of Virology 2021cited by 14position: middledoi
Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
PLoS Pathogens 2019cited by 85position: middledoi
Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
PLoS Pathogens 2019cited by 58position: middledoi
Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects
The Journal of Immunology 2016cited by 48position: middledoi
Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes
Journal of Virology 2014cited by 133position: middledoi
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
Journal of Immunological Methods 2013cited by 581position: middledoi
Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
Journal of Virology 2013cited by 360position: middledoi
Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
PLoS ONE 2013cited by 233position: middledoi
The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
AIDS Research and Human Retroviruses 2012cited by 214position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Hongmei Gao · Duke University5 papers (2013–2021)David C. Montefiori · Duke University5 papers (2013–2021)Allan C. deCamp · Fred Hutch Cancer Center3 papers (2013–2021)Robert T. Bailer · Rockefeller University3 papers (2013–2014)John R. Mascola · ApeX Therapeutics (United States)3 papers (2013–2014)Bette Korber · Los Alamos Medical Center2 papers (2013–2014)Christina Ochsenbauer · University of Alabama at Birmingham2 papers (2013–2021)Guido Ferrari · Duke University2 papers (2016–2021)Marcella Sarzotti‐Kelsoe · Duke University2 papers (2013–2013)John C. Kappes · University of Alabama at Birmingham2 papers (2013–2016)Michael S. Seaman · Harvard University2 papers (2013–2013)Bhavesh Borate · Fred Hutch Cancer Center2 papers (2016–2021)Haili Tang · Duke University1 papers (2013–2013)Chris Bailey‐Kellogg · Dartmouth College1 papers (2016–2016) · 1 papers (2013–2013)Georgia D. Tomaras · International Vaccine Institute1 papers (2021–2021)Leigh H. Fisher · Seattle Children's Hospital1 papers (2021–2021)Lynn Morris · National Center for Communicable Diseases1 papers (2021–2021)George K. Lewis · University of Maryland, Baltimore1 papers (2016–2016)Susan Zolla‐Pazner · New York University1 papers (2013–2013)